Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML
Sign Up to like & getrecommendations! Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-32306-4
Abstract: Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are chronic myeloid clonal neoplasms. To date, the only potentially curative therapy for these disorders remains allogeneic hematopoietic progenitor cell transplantation (HCT), although patient eligibility is limited… read more here.
Keywords: mds cmml; target mds; cmml; therapeutic target ... See more keywords
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022018602
Abstract: Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical… read more here.
Keywords: immature mature; mature cells; progenitor; mds cmml ... See more keywords